Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica.

Mahjoubi L, Cecchi F, Massard C, Calabro F, Gazzah A, Bahleda R, Jamme P, Gelli M, Goere D, Lacroix L, Adam J, Heukamp L, Trenta P, Hembrough T, Soria JC, Sternberg C, Ducreux M.

Tumori. 2018 Mar 1:300891618763215. doi: 10.1177/0300891618763215. [Epub ahead of print]

PMID:
29714649
2.

Targeted data-independent acquisition for mass spectrometric detection of RAS mutations in formalin-fixed, paraffin-embedded tumor biopsies.

Kim YJ, Chambers AG, Cecchi F, Hembrough T.

J Proteomics. 2018 Apr 22. pii: S1874-3919(18)30182-9. doi: 10.1016/j.jprot.2018.04.022. [Epub ahead of print]

PMID:
29684684
3.

Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma.

Maron SB, Alpert L, Kwak HA, Lomnicki S, Chase L, Xu D, O'Day E, Nagy RJ, Lanman RB, Cecchi F, Hembrough T, Schrock A, Hart J, Xiao SY, Setia N, Catenacci DVT.

Cancer Discov. 2018 Feb 15. doi: 10.1158/2159-8290.CD-17-1260. [Epub ahead of print]

PMID:
29449271
4.

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.

Yao Z, Yaeger R, Rodrik-Outmezguine VS, Tao A, Torres NM, Chang MT, Drosten M, Zhao H, Cecchi F, Hembrough T, Michels J, Baumert H, Miles L, Campbell NM, de Stanchina E, Solit DB, Barbacid M, Taylor BS, Rosen N.

Nature. 2017 Aug 10;548(7666):234-238. doi: 10.1038/nature23291. Epub 2017 Aug 2.

5.

An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer.

Xue Y, Martelotto L, Baslan T, Vides A, Solomon M, Mai TT, Chaudhary N, Riely GJ, Li BT, Scott K, Cechhi F, Stierner U, Chadalavada K, de Stanchina E, Schwartz S, Hembrough T, Nanjangud G, Berger MF, Nilsson J, Lowe SW, Reis-Filho JS, Rosen N, Lito P.

Nat Med. 2017 Aug;23(8):929-937. doi: 10.1038/nm.4369. Epub 2017 Jul 17.

6.

Proof of the quantitative potential of immunofluorescence by mass spectrometry.

Toki MI, Cecchi F, Hembrough T, Syrigos KN, Rimm DL.

Lab Invest. 2017 Mar;97(3):329-334. doi: 10.1038/labinvest.2016.148. Epub 2017 Jan 16.

7.

PS01.30: Domain-Specific c-Met Measurement by Quantitative Immunofluorescence and Mass Spectrometry in Non-Small Cell Lung Cancer: Topic: Pathology.

Toki M, Cecchi F, Hembrough T, Syrigos K, Rimm D.

J Thorac Oncol. 2016 Nov;11(11S):S287. doi: 10.1016/j.jtho.2016.09.065. Epub 2016 Oct 28. No abstract available.

8.

MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma.

Catenacci DV, Ang A, Liao WL, Shen J, O'Day E, Loberg RD, Cecchi F, Hembrough T, Ruzzo A, Graziano F.

Cancer. 2017 May 15;123(6):1061-1070. doi: 10.1002/cncr.30437. Epub 2016 Dec 7.

9.

Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment.

An E, Ock CY, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Liao WL, Cecchi F, Blackler A, Thyparambil S, Kim WH, Burrows J, Hembrough T, Catenacci DVT, Oh DY, Bang YJ.

Ann Oncol. 2017 Jan 1;28(1):110-115. doi: 10.1093/annonc/mdw442.

10.

Therapeutically Induced Changes in HER2, HER3, and EGFR Protein Expression for Treatment Guidance.

Sellappan S, Blackler A, Liao WL, O'Day E, Xu P, Thyparambil S, Cecchi F, Hembrough T, Catenacci DV.

J Natl Compr Canc Netw. 2016 May;14(5):503-7.

11.

Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib.

Hembrough T, Liao WL, Hartley CP, Ma PC, Velcheti V, Lanigan C, Thyparambil S, An E, Monga M, Krizman D, Burrows J, Tafe LJ.

Clin Chem. 2016 Jan;62(1):252-61. doi: 10.1373/clinchem.2015.245860. Epub 2015 Nov 19.

12.

Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH.

Catenacci DV, Liao WL, Zhao L, Whitcomb E, Henderson L, O'Day E, Xu P, Thyparambil S, Krizman D, Bengali K, Uzzell J, Darfler M, Cecchi F, Blackler A, Bang YJ, Hart J, Xiao SY, Lee SM, Burrows J, Hembrough T.

Gastric Cancer. 2016 Oct;19(4):1066-79. doi: 10.1007/s10120-015-0566-0. Epub 2015 Nov 18.

13.

High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.

Nuciforo P, Thyparambil S, Aura C, Garrido-Castro A, Vilaro M, Peg V, Jimenez J, Vicario R, Cecchi F, Hoos W, Burrows J, Hembrough T, Ferreres JC, Perez-Garcia J, Arribas J, Cortes J, Scaltriti M.

Mol Oncol. 2016 Jan;10(1):138-147. doi: 10.1016/j.molonc.2015.09.002. Epub 2015 Sep 15.

14.

Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue.

Catenacci DV, Liao WL, Thyparambil S, Henderson L, Xu P, Zhao L, Rambo B, Hart J, Xiao SY, Bengali K, Uzzell J, Darfler M, Krizman DB, Cecchi F, Bottaro DP, Karrison T, Veenstra TD, Hembrough T, Burrows J.

PLoS One. 2014 Jul 1;9(7):e100586. doi: 10.1371/journal.pone.0100586. eCollection 2014.

15.

Comparative evaluation of strategies for quantifying signaling pathway proteins in Ewing sarcoma.

Applebaum MA, Thomas DG, Hembrough T, Burrows J, Horvai AE, Lawlor ER, DuBois SG.

Appl Immunohistochem Mol Morphol. 2014 Sep;22(8):593-9. doi: 10.1097/PAI.0b013e3182a8d4bb.

16.

Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.

Rolle CE, Kanteti R, Surati M, Nandi S, Dhanasingh I, Yala S, Tretiakova M, Arif Q, Hembrough T, Brand TM, Wheeler DL, Husain AN, Vokes EE, Bharti A, Salgia R.

Mol Cancer Ther. 2014 Mar;13(3):576-84. doi: 10.1158/1535-7163.MCT-13-0109. Epub 2013 Dec 10.

17.

Application of selected reaction monitoring for multiplex quantification of clinically validated biomarkers in formalin-fixed, paraffin-embedded tumor tissue.

Hembrough T, Thyparambil S, Liao WL, Darfler MM, Abdo J, Bengali KM, Hewitt SM, Bender RA, Krizman DB, Burrows J.

J Mol Diagn. 2013 Jul;15(4):454-65. doi: 10.1016/j.jmoldx.2013.03.002. Epub 2013 May 11.

PMID:
23672976
18.

Selected Reaction Monitoring (SRM) Analysis of Epidermal Growth Factor Receptor (EGFR) in Formalin Fixed Tumor Tissue.

Hembrough T, Thyparambil S, Liao WL, Darfler MM, Abdo J, Bengali KM, Taylor P, Tong J, Lara-Guerra H, Waddell TK, Moran MF, Tsao MS, Krizman DB, Burrows J.

Clin Proteomics. 2012 May 3;9(1):5. doi: 10.1186/1559-0275-9-5.

19.

ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action.

Fletcher GC, Brokx RD, Denny TA, Hembrough TA, Plum SM, Fogler WE, Sidor CF, Bray MR.

Mol Cancer Ther. 2011 Jan;10(1):126-37. doi: 10.1158/1535-7163.MCT-10-0574. Epub 2010 Dec 21.

20.

The hematopoietic-specific beta1-tubulin is naturally resistant to 2-methoxyestradiol and protects patients from drug-induced myelosuppression.

Escuin D, Burke PA, McMahon-Tobin G, Hembrough T, Wang Y, Alcaraz AA, Leandro-García LJ, Rodríguez-Antona C, Snyder JP, Lavallee TM, Giannakakou P.

Cell Cycle. 2009 Dec;8(23):3914-24. Epub 2009 Dec 16.

PMID:
19901556
21.

Expression and proinflammatory role of proteinase-activated receptor 2 in rheumatoid synovium: ex vivo studies using a novel proteinase-activated receptor 2 antagonist.

Kelso EB, Ferrell WR, Lockhart JC, Elias-Jones I, Hembrough T, Dunning L, Gracie JA, McInnes IB.

Arthritis Rheum. 2007 Mar;56(3):765-71.

22.

Therapeutic promise of proteinase-activated receptor-2 antagonism in joint inflammation.

Kelso EB, Lockhart JC, Hembrough T, Dunning L, Plevin R, Hollenberg MD, Sommerhoff CP, McLean JS, Ferrell WR.

J Pharmacol Exp Ther. 2006 Mar;316(3):1017-24. Epub 2005 Oct 31.

23.

Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity.

Hembrough TA, Ruiz JF, Swerdlow BM, Swartz GM, Hammers HJ, Zhang L, Plum SM, Williams MS, Strickland DK, Pribluda VS.

Blood. 2004 May 1;103(9):3374-80. Epub 2004 Jan 22.

24.

Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism.

Hembrough TA, Swartz GM, Papathanassiu A, Vlasuk GP, Rote WE, Green SJ, Pribluda VS.

Cancer Res. 2003 Jun 1;63(11):2997-3000.

25.

Cytokeratin 8 functions as a major plasminogen receptor in select epithelial and carcinoma cells.

Gonias SL, Hembrough TA, Sankovic M.

Front Biosci. 2001 Nov 1;6:D1403-11. Review.

PMID:
11689350
26.

Tissue factor pathway inhibitor inhibits endothelial cell proliferation via association with the very low density lipoprotein receptor.

Hembrough TA, Ruiz JF, Papathanassiu AE, Green SJ, Strickland DK.

J Biol Chem. 2001 Apr 13;276(15):12241-8. Epub 2001 Jan 17.

27.

Characterization of the binding sites for plasminogen and tissue-type plasminogen activator in cytokeratin 8 and cytokeratin 18.

Kralovich KR, Li L, Hembrough TA, Webb DJ, Karns LR, Gonias SL.

J Protein Chem. 1998 Nov;17(8):845-54.

PMID:
9988531
30.

Supplemental Content

Loading ...
Support Center